Celgene Co. (NASDAQ:CELG) Shares Sold by Rikoon Group LLC

Rikoon Group LLC reduced its holdings in Celgene Co. (NASDAQ:CELG) by 4.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,174 shares of the biopharmaceutical company’s stock after selling 100 shares during the quarter. Rikoon Group LLC’s holdings in Celgene were worth $216,000 at the end of the most recent quarter.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several other institutional investors and hedge funds have also bought and sold shares of CELG. Thomasville National Bank lifted its holdings in Celgene by 1.1% in the second quarter. Thomasville National Bank now owns 32,802 shares of the biopharmaceutical company’s stock valued at $3,032,000 after acquiring an additional 365 shares during the period. Syquant Capital Sas acquired a new position in Celgene in the second quarter valued at approximately $35,118,000. WINTON GROUP Ltd lifted its holdings in Celgene by 50.1% in the second quarter. WINTON GROUP Ltd now owns 196,768 shares of the biopharmaceutical company’s stock valued at $18,189,000 after acquiring an additional 65,656 shares during the period. Calton & Associates Inc. lifted its holdings in Celgene by 9.5% in the second quarter. Calton & Associates Inc. now owns 5,277 shares of the biopharmaceutical company’s stock valued at $488,000 after acquiring an additional 456 shares during the period. Finally, Contravisory Investment Management Inc. acquired a new position in Celgene in the second quarter valued at approximately $62,000. 72.31% of the stock is owned by institutional investors and hedge funds.

In other news, insider Terrie Curran sold 11,338 shares of the company’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total value of $1,114,185.26. Following the transaction, the insider now owns 13,493 shares of the company’s stock, valued at approximately $1,325,957.11. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.39% of the company’s stock.

Shares of Celgene stock traded up $0.54 on Friday, reaching $109.54. The company’s stock had a trading volume of 5,706,800 shares, compared to its average volume of 6,764,924. Celgene Co. has a 52-week low of $58.59 and a 52-week high of $109.75. The stock has a 50-day moving average price of $102.54 and a 200-day moving average price of $96.76. The company has a market capitalization of $76.64 billion, a P/E ratio of 14.39, a PEG ratio of 0.51 and a beta of 1.41. The company has a quick ratio of 2.80, a current ratio of 2.89 and a debt-to-equity ratio of 1.51.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $2.99 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.70 by $0.29. Celgene had a return on equity of 78.15% and a net margin of 34.63%. The business had revenue of $4.52 billion for the quarter, compared to analyst estimates of $4.39 billion. During the same quarter in the prior year, the company posted $2.29 EPS. The company’s quarterly revenue was up 16.1% on a year-over-year basis. Sell-side analysts forecast that Celgene Co. will post 10.7 earnings per share for the current fiscal year.

A number of brokerages have issued reports on CELG. Cowen reissued a “hold” rating and issued a $102.00 price target on shares of Celgene in a report on Tuesday, July 30th. Leerink Swann set a $115.00 price target on Celgene and gave the company a “hold” rating in a report on Friday, November 1st. Wells Fargo & Co set a $110.00 price target on Celgene and gave the company a “hold” rating in a report on Friday, November 1st. Robert W. Baird cut Celgene from an “outperform” rating to a “neutral” rating and set a $101.00 price objective for the company. in a research report on Friday, November 1st. Finally, Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective for the company in a research report on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, nineteen have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $97.31.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Read More: Understanding Market Liquidity

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Leave a Reply

Your email address will not be published. Required fields are marked *